Teva Pharmaceutical Industries Ltd (TEVA)

[genisi]

Now that Teva is approved for Neupogen and they have CoGenesys's tech, I bet they will go for PEG-filgrastim (Neulasta).
The advantage of Neulasta over Neupogen is it only requires one administration per cycle of chemotherapy due to its increased half-life. Product sales in 2006 were $2,300 MM and growing at ~ 12%. US patent expiry approximately 2017.